Skip to content

Clinical Efficacy of Repetitive Transcranial Magnetic Stimulation in the Treatment of Post-Stroke Diaphragmatic Dysfunction and Its Association with Brain-Derived Neurotrophic Factor Gene Polymorphisms

Clinical Efficacy of Repetitive Transcranial Magnetic Stimulation in the Treatment of Post-Stroke Diaphragmatic Dysfunction and Its Association with Brain-Derived Neurotrophic Factor Gene Polymorphisms

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126165
Enrollment
Unknown
Registered
2026-06-04
Start date
2026-01-07
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-stroke diaphragmatic dysfunction

Interventions

Group A (rTMS stimulation plus conventional rehabilitation training) :Repetitive transcranial magnetic stimulation(rTMS)
Group B (conventional rehabilitation training plus sham stimulation):Conventional rehabilitation training

Sponsors

The Second Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. No gender restriction, age 18-75 years; 2. First-ever supratentorial stroke patients, within 2 weeks to 6 months of onset; 3. Presence of diaphragm dysfunction (diaphragm thickening fraction less than 20%, diaphragm thickening fraction = (end-inspiratory diaphragm thickness at rest - end-expiratory diaphragm thickness at rest) ÷ end-expiratory diaphragm thickness at rest × 100%); 4. Conscious and alert: (1) MMSE >= 21, assess diaphragm thickening fraction, diaphragm excursion, measure serum BDNF concentration, MIP, MEP, FVC, FEV1; (2) MMSE < 21, assess diaphragm thickening fraction, diaphragm excursion, measure serum BDNF concentration.

Exclusion criteria

Exclusion criteria: 1. Patients with respiratory system diseases such as chronic obstructive pulmonary disease, pulmonary tuberculosis, and lung cancer; 2. Patients whose condition has worsened and vital signs are unstable; 3. Patients with cerebellar and brainstem stroke; 4. Patients with comorbid myasthenia gravis or phrenic nerve paralysis; 5. Patients with severe impairment of important organ functions or critical illness; 6. Patients with contraindications to TMS treatment, such as implanted cardiac pacemakers, epilepsy, or cranial defects on the affected side.

Design outcomes

Primary

MeasureTime frame
Diaphragmatic thickening fraction;BDNF gene polymorphism;

Secondary

MeasureTime frame
Diaphragmatic excursion;Maximal Inspiratory Pressure;Maximal Expiratory Pressure;forced vital capacity;Serum BDNF concentration;

Countries

China

Contacts

Public ContactWenli Wang

The Second Affiliated Hospital of Kunming Medical University

wangwenli@kmmu.edu.cn+86 158 0880 3641

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026